Drug/Small Molecule:

vindesine

Overview

Generic Names:	Desacetylvinblastine Amide Sulfate; Vindesine Sulfate
Trade Names:	DAVA; Eldesine; Eldisine
PharmGKB Accession Id:	PA10232

Description

Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols). [PubChem]

Indication

For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis

ATC Therapeutic Category

• L01CA:Vinca alkaloids and analogues

Pharmacology and Interactions

Mechanism Of Action

Vindesine acts by causing the arrest of cells in metaphase mitosis through its interaction with tubulin. The drug is cell-cycle specific for the S phase.

Pharmacology

Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Protein Binding

65-75%

Half Life

24 hours.

Chemical Properties

Chemical Formula:

C₄₃H₅₅N₅O₇

SMILES Code:

CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CC[N@@]9[C@H]7[C@@](C=CC9
)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O

(Format: OpenEye Isomeric)

Molecular Weight ( average / monoisotopic )

753.9261 / 753.4101

Curated Information

The following genes are in curated knowledge about this drug.

	Gene	Relationship	Evidence
	ABCB1	PK	Pathways
	ABCB11	PK	Pathways
	ABCB4	PK	Pathways
	ABCC1	PK	Pathways
	ABCC10	PK	Pathways
	ABCC2	PK	Pathways
	CYP3A4	PK	Pathways
	CYP3A5	PK	Pathways
	RALBP1	PK	Pathways

Non-Curated Information

A list of non-curated publications that mention this drug along with other genes is available.

Metabolizing Enzymes

• CYP3A4

Drug Targets

• TUBB1

PharmGKB Curated Pathways

• Vinca Alkaloids PK

Non-Curated Information

A list of non-curated publications that mention this drug along with other drugs is available.

Curated Information

The following diseases are in curated knowledge about this drug.

	Disease	Relationship	Evidence
	Hodgkin Disease	PK	Pathways
	Lymphoma, Non-Hodgkin	PK	Pathways
	Multiple Myeloma	PK	Pathways
	Precursor Cell Lymphoblastic Leukemia-Lymphoma	PK	Pathways

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

LinkOuts

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.